IDRx’s lead candidate IDRX-42 is being investigated in a Phase I/IIb trial in patients with advanced gastrointestinal stromal tumours.

Over the weekend, Chiefs Wire’s Ed Easton Jr. spoke to accomplished actress Gina Torres at a remarkable and informative women ...

chief commercial officer at GSK, said in Monday’s announcement. Just last August, IDRx raised a $120 million Series B financing led by RA Capital Management, Commodore Capital and Blackstone ...

Ballentine Partners LLC boosted its holdings in shares of GSK plc (NYSE:GSK – Free Report) by 40.7% in the fourth quarter, ...

GSK (NYSE:GSK – Get Free Report) was downgraded by investment analysts at StockNews.com from a “strong-buy” rating to a “buy” ...

He added: 'Combining our experience to date with GSK's expertise in GI cancers, global clinical development capability, and strong commercial presence in oncology will help to accelerate the ...

In the announcement accompanying the acquisition, GSK's chief commercial officer Luke Miels said: “IDRX-42 complements our growing portfolio in gastrointestinal cancers. This acquisition is ...